علاج اللمفومة الجريبية المتحولة بعد العلاج الكيميائي السابق بالأنثراسيكلين

References

1. The treatment of patients with tFL previously exposed to anthracyclines with or without rituximab is varied and, in general, involves second-line regimens used for DLBCL in patients who are eligible for consolidation with HDT-ASCR.
2. Offer second-line salvage chemotherapy regimens used for DLBCL in tFL who have received prior anthracycline and are fit for HDT-ASCR.
3. Consider HDT-ASCR in tFL patients previously treated with R-chemotherapy, who respond to salvage therapy and are fit for HDT-ASCR.